Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the ‘Spinal Tap’

Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183-198.

Salzer J. , Sundstrom P. , Svenningsson A. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287-292.

Lycke JN , Karlsson JE , Andersen O. , Rosengren LE Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404.

Malmestrom C. , Haghighi S. , Rosengren L. , Andersen O. , Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-1725.

Haghighi S. , Andersen O. , Oden A. , Rosengren L. Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol Scand 2004; 109: 97-99.

Petzold A. , Eikelenboom MJ , Keir G. , et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005; 76: 206-211.

Semra YK , Seidi OA , Sharief MK Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002; 122: 132-139.

Norgren N. , Rosengren L. , Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987: 25-31.

Eikelenboom MJ , Petzold A. , Lazeron RH , et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003; 60: 219-223.

Petzold A. , Rejdak K. , Plant GT Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004; 75: 1178-1180.

Petzold A. , Brassat D. , Mas P. , et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004 ; 10: 281-283.